Global and Japan Vortioxetine Market Insights, Forecast to 2027

Vortioxetine is an atypical antipsychotic and antidepressant indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. 

Market Analysis and Insights: Global and Japan Vortioxetine Market
This report focuses on global and Japan Vortioxetine market.
In 2020, the global Vortioxetine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Vortioxetine market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Vortioxetine Scope and Market Size
Vortioxetine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Vortioxetine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Vortioxetine market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
5 Mg Tablets
10 Mg Tablet
15 Mg Tablet
20 Mg Tablet

Segment by Application
Depression
Generalized Anxiety Disorder
Attention Deficit Hyperactivity Disorder
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Takeda
Lundbeck
CGeneTech